Clinical Trial Update: A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating toripalimab as adjuvant therapy after surgical resection of high-risk renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: High-risk Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING